Medivation, Inc. (MDVN)

81.44
NASDAQ
Prev Close 81.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Thursday's Divergence

As the S&P hit another bull market high, the Nasdaq 100 ground sideways.

Top Insider Trades: JAKK SPB YELP MDVN

Top Insider Trades: JAKK SPB YELP MDVN

The top 10 open-market insider purchases and sales filed at the SEC Tuesday.

Medivation Inc. (MDVN): Drugs' Featured Underachiever Of The Day

Medivation Inc. (MDVN): Drugs' Featured Underachiever Of The Day

Medivation was a leading decliner within the drugs industry, falling 73 cents (-1.4%) to $49.82 on light volume.

Medivation Inc. (MDVN): Today's Featured Health Care Laggard

Medivation Inc. (MDVN): Today's Featured Health Care Laggard

Medivation was a leading decliner within the health care sector, falling 63 cents (-1.3%) to $48.36 on average volume.

Shocker! Sell-Sider Admits Dendreon Buy Rating Was Mistake

Shocker! Sell-Sider Admits Dendreon Buy Rating Was Mistake

ISI Group's Mark Schoenebaum offers refreshing mea culpa on Dendreon bullishness.

Medivation Stock Falls On Unusually High Volume (MDVN)

Medivation Stock Falls On Unusually High Volume (MDVN)

Medivation (Nasdaq:MDVN) is trading at unusually high volume Friday with 2.3 million shares changing hands. It is currently at two times its average daily volume and trading down $3.10 (-6.3%).

3 Stocks Pushing The Health Care Sector Lower

3 Stocks Pushing The Health Care Sector Lower

TheStreet Ratings group would like to highlight 3 stocks pushing the health care sector lower today, Feb. 28, 2013.

Medivation Rises On Unusually High Volume (MDVN)

Medivation Rises On Unusually High Volume (MDVN)

Medivation (Nasdaq:MDVN) is trading at unusually high volume Friday with 2.1 million shares changing hands. It is currently at 2.2 times its average daily volume and trading up $1.57 (+2.9%).

Medivation Inc. (MDVN): Today's Featured Health Care Laggard

Medivation Inc. (MDVN): Today's Featured Health Care Laggard

Medivation was a leading decliner within the health care sector, falling 59 cents (-1.1%) to $54.28 on light volume.

Medivation Stock Hits New 52-Week High (MDVN)

Medivation Stock Hits New 52-Week High (MDVN)

Medivation (Nasdaq:MDVN) hit a new 52-week high Tuesday as it is currently trading at $59.16, above its previous 52-week high of $58.83 with 855,030 shares traded as of 10:51 a.m. ET. Average volume has been 962,500 shares over the past 30 days.

J.P. Morgan Healthcare Confab Live Blog: Day One

J.P. Morgan Healthcare Confab Live Blog: Day One

Live, interactive coverage of the biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.

The Twitterverse's Biotech Stock Picks for 2013

The Twitterverse's Biotech Stock Picks for 2013

TheStreet's readers took to Twitter to offer their biotech stock predictions for 2013.

J.P. Morgan: Biotech Stocks Heading Higher in 2013

J.P. Morgan: Biotech Stocks Heading Higher in 2013

Strong fundamentals and pipelines should lead to another year of biotech outperformance, the bank predicts.

13 Biotech Stock Predictions for 2013

13 Biotech Stock Predictions for 2013

TheStreet's Adam Feuerstein gazes into his crystal ball to offer his 2013 biotech stock forecast.

Best Biotech CEO of 2012: Your Vote Counts

Best Biotech CEO of 2012: Your Vote Counts

CEOs from Onyx Pharma, Gilead Sciences, Regeneron Pharma and Sarepta Therapeutics vie for title.

Medivation Inc. (MDVN): Today's Featured Health Care Laggard

Medivation Inc. (MDVN): Today's Featured Health Care Laggard

Medivation was a leading decliner within the health care sector, falling $1.15 (-2.4%) to $46.26 on average volume.

Dendreon: No-Drama Quarter Seen As Big Win

Dendreon: No-Drama Quarter Seen As Big Win

Provenge sales were light but no blowups left investors happier about Dendreon's future.

Medivation Prostate Cancer Drug Launches Hot

Medivation Prostate Cancer Drug Launches Hot

Medivation's Xtandi jumps out of the launch gate with strong sales of $14 million.

Biotech Earnings Preview: Vertex, Dendreon, Incyte, Medivation, Onyx (Updated)

Biotech Earnings Preview: Vertex, Dendreon, Incyte, Medivation, Onyx (Updated)

Third-quarter earnings announcements have been rescheduled due to Hurricane Sandy.

Biotech Stock Live Chat

Biotech Stock Live Chat

TheStreet columnist Adam Feuerstein takes your biotech investing questions.

Biotech Earnings Preview: Vertex, Onyx, Dendreon, Medivation

Biotech Earnings Preview: Vertex, Onyx, Dendreon, Medivation

A busy week for biotech earnings includes the first look at cancer drug launches from Onyx and Medivation.

The Next Big Thing in Biotech: Earnings

The Next Big Thing in Biotech: Earnings

Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.

Medivation Inc. (MDVN): Today's Featured Drugs Laggard

Medivation Inc. (MDVN): Today's Featured Drugs Laggard

Medivation was a leading decliner within the drugs industry, falling 96 cents (-1.8%) to $52.70 on average volume.

Medivation Stock Hits New 52-Week High (MDVN)

Medivation Stock Hits New 52-Week High (MDVN)

Medivation (Nasdaq:MDVN) hit a new 52-week high Friday as it is currently trading at $58.27, above its previous 52-week high of $58.26 with 551,086 shares traded as of 2:41 p.m. ET. Average volume has been 937,400 shares over the past 30 days.

Medivation Reaches New 52-Week High (MDVN)

Medivation Reaches New 52-Week High (MDVN)

Medivation (Nasdaq:MDVN) hit a new 52-week high Thursday as it is currently trading at $56.60, above its previous 52-week high of $56.50 with 1.2 million shares traded as of 1:56 p.m. ET. Average volume has been 935,600 shares over the past 30 days.

Peregrine Pharma: Not Good Enough to Own, Too Risky to Short

Peregrine Pharma: Not Good Enough to Own, Too Risky to Short

Nate Sadeghi examines Peregrine's lung cancer drug bavituximab

Peregrine Pharma's Lung Cancer Drug: Boffo Survival Benefit, But How Real?

Peregrine Pharma's Lung Cancer Drug: Boffo Survival Benefit, But How Real?

More data will help Peregrine convince skeptics that bavituximab is a real lung cancer drug.

Netflix, Medicis, Korn/Ferry Are Market Movers

Netflix, Medicis, Korn/Ferry Are Market Movers

Netflix, Medicis, Korn/Ferry, Consol Energy are market movers

Cramer's 6 Stocks in 60 Seconds: MANU MDVN GME AAPL UNP HEK

Cramer's 6 Stocks in 60 Seconds: MANU MDVN GME AAPL UNP HEK

Medivation is a real winner but Manchester United should be avoided, Cramer said.

Remember What Really Moves Stocks

Motivated CEOs, innovative products and smart deals count more than macro events.